Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

Study finds AFREZZA comparable to standard of care insulin therapy

Pulmonary function test results (PFTs) in patients treated with AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, at follow-up measurements were similar to PFT results observed in patients receiving standard antidiabetic therapy, according to data presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster #267).

24 Apr 2010

WellPoint responds to HHS letter on singling out women with breast cancer for rescission

I was disappointed to read your letter regarding the media report published in Reuters yesterday as well as your assertion that WellPoint "deliberately works to deny coverage for women diagnosed with breast cancer." Both your statement and Mr. Waas' piece are inaccurate and grossly misrepresent WellPoint's efforts to help prevent, detect, and treat the 1 in 8 of our 34 million members nationwide affected by breast cancer.

24 Apr 2010

AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetes

Diabetes treatment regimens containing AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, provide glucose control similar to standard insulin therapy along with weight loss and reduced incidence of hypoglycemia in patients with Type 1 diabetes and poorly controlled blood sugar levels, according to a two-year study presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster #283).

24 Apr 2010

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.

24 Apr 2010

Aragon Pharmaceuticals raises $22M through Series B financing

Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing.

23 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

Increase in mammographic density associated with increase of breast cancer in EPT study participants

An increase in breast density appears to be the culprit behind an increase of breast cancer found in women participating in the estrogen and progestin therapy study, a part of the Women's Health Initiative (WHI). That is the finding of a new WHI analysis led by Celia Byrne, PhD, assistant professor at Georgetown Lombardi Comprehensive Cancer Center, and presented during the AACR 101st Annual Meeting 2010 in Washington, DC.

22 Apr 2010

NPS Pharmaceuticals closes public offering of common stock shares

NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 10,350,000 shares of its common stock, including 1,350,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered by the Company. Net proceeds were approximately $53.3 million after deducting underwriting discounts and commissions, and estimated offering expenses. Canaccord Adams acted as sole book-running manager and Needham & Company, LLC acted as co-manager for the offering.

22 Apr 2010

CVS Caremark survey results of specialty pharmacy patients

CVS Caremark today announced results of a survey of the company's specialty pharmacy patients that provides insights into their views on medication adherence and their perceptions about the role of their specialty pharmacy. The survey results show nearly 70 percent of respondents believe their specialty pharmacy team played an important role in encouraging them to take their specialty medications as prescribed.

21 Apr 2010

EGFR levels may help early detection of breast cancer

Levels of epidermal growth factor receptor (EGFR) may be elevated in the blood of women within 17 months prior to their breast cancer diagnosis, according to findings presented at the American Association for Cancer Research 101st Annual Meeting 2010, held here April 17-21.

21 Apr 2010

Decrease in breast density linked to reduced risk of breast cancer

A decrease in breast density, or the proportion of fibroglandular tissue depicted on the mammogram image, over a number of years is associated with decreased risk of breast cancer, researchers from the Mayo Clinic campus in Minnesota report at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010.

21 Apr 2010

CINJ researches identify new drug candidates that inhibits prostate cancer growth

Trying to break down a barrier that prevents effective treatment of prostate cancer, researchers from The Cancer Institute of New Jersey (CINJ) have identified candidate drugs that block a key protein responsible for tumor growth.

21 Apr 2010

High BMI can raise risk of postmenopausal breast cancer

Reported mid-life increase in body mass index (BMI) may lead to substantially higher risk of postmenopausal breast cancer, according to results of a prospective cohort study presented at the American Association for Cancer Research 101st Annual Meeting 2010, held here April 17-21.

21 Apr 2010

Researchers identify potential drug target for treatment of Alzheimer's disease

Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimer's disease: a receptor that is embedded in the membrane of neurons and other cells.

21 Apr 2010

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

20 Apr 2010

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

Myriad Pharmaceuticals, Inc. today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with Javelin Pharmaceuticals.

19 Apr 2010

Updated clinical guidelines presented at EAU Anniversary Congress

A number of updated guidelines are presented at the Anniversary Congress of the European Association of Urology (EAU) held in Barcelona, from 16 through 20 April. The abridged versions - Pocket Guidelines - which are based on the extended text documents will also be available in Barcelona to all EAU members and press.

17 Apr 2010

Men with prostate cancer may face increased risk of thromboembolism

Men with prostate cancer, particularly those receiving hormone therapy, may face an increased risk of blood clots or 'thromboembolism', scientists at King's College London have found.

17 Apr 2010

NPS Pharmaceuticals prices 9,000,000 shares of common stock at $5.50 per share

NPS Pharmaceuticals, Inc. today announced that it has priced an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $5.50 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $46.2 million.

17 Apr 2010

Akela to terminate lease payment agreement

Akela a leader in the development of therapeutics for the treatment of pain and its wholly owned subsidiary, PharmaForm, a leader in the contract pharmaceutical development and manufacturing business, today announced that it has reached agreement with HEP Davis Spring, L.P. to terminate its lease located at 9825 Spectrum Drive, Austin, Texas, eliminating $14,500,000 in future lease payment obligations to the Company.

17 Apr 2010